HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC) WHO RECEIVED FIRST-LINE (1L) TREATMENT: RESULTS FROM IMPACT UC II

被引：0
|
作者：
Bilen, M. A. [1 ]
Diessner, B. [2 ]
White, J. [2 ]
Kirker, M. [3 ]
Liu, F. [4 ]
Nguyen, A. [2 ]
Gharibian, N. [3 ]
Devgan, G. [3 ]
Katzenstein, H. [4 ]
Bhanegaonkar, A. [4 ]
机构：
[1] Winship Canc Inst Emory Univ, Atlanta, GA USA
[2] Optum, Eden Prairie, MN USA
[3] Pfizer, New York, NY USA
[4] EMD Serono, Rockland, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE390
引用
下载
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [1] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COST STUDIES IN PATIENTS RECEIVING FIRST-LINE (1L) THERAPY FOR ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Auti, P.
    Braun, N.
    Arca, E.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S70 - S70
  • [2] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
    Bilen, M. A.
    Xi, A. D.
    Wong, A.
    Schroeder, A.
    Kim, R.
    Liu, F. X.
    Peng, J.
    Robinson, S.
    Bhanegaonkar, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S713 - S713
  • [3] SURVIVAL ANALYSES AND INDIRECT TREATMENT COMPARISONS (ITCS) IN FIRST-LINE METASTATIC UROTHELIAL CARCINOMA (1L MUC)
    Jevdjevic, M.
    Nickel, K.
    Teitsson, S.
    Kurt, M.
    Broughton, E.
    Jain, R.
    Kroep, S.
    VALUE IN HEALTH, 2022, 25 (07) : S333 - S333
  • [4] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND RELATED DIRECT HEALTHCARE COSTS FOR PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC): FINDINGS FROM A RETROSPECTIVE OBSERVATIONAL COHORT STUDY IN A CLINICAL PRACTICE SETTING IN ITALY
    Kearney, M.
    Thompson, A.
    Kirker, M.
    Gharibian, N.
    Costa, N.
    Furegato, M.
    Pacheco, C.
    Issa, S.
    Sciattella, P.
    Scortichini, M.
    Mennini, F. S.
    VALUE IN HEALTH, 2023, 26 (12) : S154 - S154
  • [5] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
    Aragon-Ching, J. B.
    Grivas, P.
    Loriot, Y.
    Bellmunt, J.
    Wang, J.
    Michelon, E.
    di Pietro, A.
    Powles, T. B.
    Sridhar, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1343 - S1343
  • [6] Healthcare costs and resource utilization associated with select severe adverse events in patients with metastatic urothelial cancer treated with first-line systemic therapies
    Shenolikar, Rahul
    Laliberte, Francois
    Doleh, Yunes
    Cavanaugh, Cristi
    DerSarkissian, Maral
    Grivas, Petros
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 300 - 301
  • [7] TREATMENT PATTERN AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA (MUC) AMONG MEDICARE FEE-FOR-SERVICE (FFS) BENEFICIARIES: RESULTS FROM IMPACT UC
    Bilen, M. A.
    Xi, A.
    Schroeder, A.
    Kim, R.
    Liu, F.
    Wong, A.
    Peng, J.
    Jones, B.
    Robinson, S. B.
    Bhanegaonkar, A.
    VALUE IN HEALTH, 2021, 24 : S65 - S65
  • [8] HEALTHCARE COST AND HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG FIRST-LINE (1L) TREATED PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC): ANALYSIS OF SEER-MEDICARE LINKED CLAIMS IN THE US
    Rai, P.
    Turkistani, F.
    Momo, H.
    Min, J.
    Syed, S. S.
    Paratane, D.
    Rajagopalan, K.
    Aggarwal, H.
    VALUE IN HEALTH, 2024, 27 (06) : S394 - S394
  • [9] Prevalence of PD-L1 expression in first-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC).
    Grivas, Petros
    Morgans, Alicia K.
    Lotan, Yair
    Gregg, Jeffrey P.
    Geynisman, Daniel M.
    Friedlander, Terence W.
    Agarwal, Piyush K.
    Tesic-Schnell, Marija
    Bernstein, Andrew
    Makari, Doris
    Meeks, Joshua J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [10] Healthcare resource utilization and costs in patients with HIV-1 who switched first-line antiretroviral therapy
    Mao, Jianbin
    Johnson, Michael P.
    McPheeters, Jeffrey T.
    Prajapati, Girish
    Beyer, Andrew P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (11) : 1945 - 1953
12345